

## Anti-DARC Antibody (8R325)

## Product Details

Ig Type:	Rabbit IgG
Reactivity:	Human
Conjugation:	Unconjugated
Clone:	8R325
Purification:	Affinity-chromatography

## Applications

Verified Activity:	Overlay Peak curve showing 293 cells stained with TMAH-00330 (red line) at 1:50. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1µg/1*10 <sup>6</sup> cells) for 45min at 4°C. The secondary antibody used was FITC-conjugated Goat Anti-rabbit IgG (H+L) at 1:200 dilution for 35min at 4°C. Control antibody (green line) was rabbit IgG (1µg/1*10 <sup>6</sup> cells) used under the same conditions. Acquisition of >10,000 events was performed.
Application:	ELISA, FCM
Recommended	FCM:1:50-1:200.

## Properties

Stability & Storage:	Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles.
Shipping:	Shipping with blue ice.

## Antigen Details

Immunogen:	A synthetic peptide: Human DARC
Antigen Species:	Human
Gene ID:	2532
Uniprot ID:	Q16570
Biology Area:	Cardiovascular, Immunology, Microbiology, Signal transduction

## Research Background

Atypical chemokine receptor that controls chemokine levels and localization via high-affinity chemokine binding that is uncoupled from classic ligand-driven signal transduction cascades, resulting instead in chemokine sequestration, degradation, or transcytosis. Also known as interceptor (internalizing receptor) or chemokine-scavenging receptor or chemokine decoy receptor. Has a promiscuous chemokine-binding profile, interacting with inflammatory chemokines of both the CXC and the CC subfamilies but not with homeostatic chemokines. Acts as a receptor for chemokines including CCL2, CCL5, CCL7, CCL11, CCL13, CCL14, CCL17, CXCL5, CXCL6, IL8/CXCL8, CXCL11, GRO, RANTES, MCP-1, TARC and also for the malaria parasites *P.vivax* and *P.knowlesi*. May regulate chemokine bioavailability and, consequently, leukocyte recruitment through two distinct mechanisms: when expressed in endothelial cells, it sustains the abluminal to luminal transcytosis of tissue-derived chemokines and their subsequent presentation to circulating leukocytes; when expressed in erythrocytes, serves as blood reservoir of

cognate chemokines but also as a chemokine sink, buffering potential surges in plasma chemokine levels.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481